Misplaced Pages

This is an old revision of this page, as edited by BogBot (talk | contribs) at 02:06, 1 September 2011 (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pazopanib

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a610013
License data	EU EMA: by INN US FDA: Pazopanib
Routes of administration	Oral
ATC code	L01XE11 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hepatic (CYP3A4, 1A2 and 2C8-mediated)
Elimination half-life	31 hours (mean)
Excretion	Mostly fecal
Identifiers
IUPAC name 5--2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
CAS Number	444731-52-6
PubChem CID	11525740
ChemSpider	9700526
UNII	7RN5DR86CK
ChEMBL	ChEMBL477772
CompTox Dashboard (EPA)	DTXSID8048733
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	437.517 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES Cl.O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma by the U.S. Food and Drug Administration. Pazopanib may also be active in ovarian cancer and soft tissue sarcoma. Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.

References

1. "FDA Approves GlaxoSmithKline's Votrient(TM) For Advanced Renal Cell Cancer". Medical News Today. 20 October 2009. Retrieved 8 June 2010.
2. ^ "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10.
3. Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1200/JCO.2008.21.3223, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1200/JCO.2008.21.3223 instead.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Orphan drugs
• Receptor tyrosine kinase inhibitors
• Sulfonamides
• Aromatic amines
• Pyrimidines
• Indazoles
• Anilines
• Antineoplastic and immunomodulating drug stubs